之江生物: 之江生物：关于增加使用部分暂时闲置募集资金进行现金管理的公告

Core Viewpoint - The company has approved an increase in the use of temporarily idle raised funds for cash management, raising the limit from RMB 880 million to RMB 940 million, aimed at enhancing fund utilization efficiency and maximizing shareholder returns [1][4][8] Group 1: Fundraising Overview - The company raised a total of RMB 2,103.78 million through its initial public offering, with a net amount of RMB 1,942.32 million after deducting issuance costs [2] - The total investment amount for the projects funded by the raised capital is RMB 1,355.89 million [3] Group 2: Cash Management Increase - The company will use an additional RMB 60 million of temporarily idle raised funds for cash management, bringing the total to RMB 940 million, with a validity period of 12 months from the board's approval [4][5] - The cash management products will include low-risk, capital-preserving, and liquid options such as principal-protected financial products, structured deposits, and large-denomination certificates of deposit [5] Group 3: Implementation and Oversight - The chairman of the company is authorized to make investment decisions and sign relevant contracts within the approved limits and timeframe [5] - The company will comply with relevant regulations and timely disclose information regarding the cash management activities [5][6] Group 4: Impact on the Company - The increase in cash management is designed to ensure that the company's fundraising projects proceed smoothly and that the safety of the raised funds is maintained, without affecting the company's normal operations [6] - The cash management activities are expected to generate additional investment returns for the company and its shareholders [6][7] Group 5: Opinions and Compliance - The supervisory board supports the increase in cash management, stating it will enhance fund efficiency and not harm the interests of the company or minority shareholders [7] - The sponsor has confirmed that the increase in cash management complies with regulatory requirements and does not alter the intended use of the raised funds [8]